BRAF and neoplasm: Many recent data indicate that the aggressive behavior of a DTC (including a high likelihood of tumor recurrence) is more likely when an oncogenic mutation is present, and in particular a BRAF mutation occurring with a mutated promoter of TERT, PIK3CA, TP53, or AKT1 [20].